Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Garrett

Showing results (301-310 of 330) with videos related to

Pageof 33
Sort By:
The Journal of Urology|April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot studyAdam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.
JCO Precision Oncology|April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyErin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
JCO Clinical Cancer Informatics|August 15, 2024
Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non-Small Cell Lung Cancer Treated With ChemotherapyBrittany A McKelvey, Elizabeth Garrett-Mayer, Donna R Rivera, et al.
JCO Precision Oncology|December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyNitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.
JCO Precision Oncology|December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyFunda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Annals of Surgical Oncology|September 21, 2010
Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes fails to predict breast cancer recurrence: a final analysis of a prospective multi-institutional cohort studyCarla Suzanne Fisher, David J Cole, Michael Mitas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyTimothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Cell Metabolism|November 14, 2017
CD38-NAD<sup>+</sup>Axis Regulates Immunotherapeutic Anti-Tumor T Cell ResponseShilpak Chatterjee, Anusara Daenthanasanmak, Paramita Chakraborty, et al.
Pageof 33

Showing results (301-310 of 330) with videos related to

Sort By:
Pageof 33
The Journal of Urology|April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot studyAdam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.
JCO Precision Oncology|April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyErin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
JCO Clinical Cancer Informatics|August 15, 2024
Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non-Small Cell Lung Cancer Treated With ChemotherapyBrittany A McKelvey, Elizabeth Garrett-Mayer, Donna R Rivera, et al.
JCO Precision Oncology|December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyNitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.
JCO Precision Oncology|December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyFunda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Annals of Surgical Oncology|September 21, 2010
Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes fails to predict breast cancer recurrence: a final analysis of a prospective multi-institutional cohort studyCarla Suzanne Fisher, David J Cole, Michael Mitas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyTimothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Cell Metabolism|November 14, 2017
CD38-NAD<sup>+</sup>Axis Regulates Immunotherapeutic Anti-Tumor T Cell ResponseShilpak Chatterjee, Anusara Daenthanasanmak, Paramita Chakraborty, et al.
Pageof 33